| Similar Articles |
|---|
 |
The Motley Fool
October 31, 2007
Brian Lawler |
Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division.   |
The Motley Fool
April 16, 2008
Brian Lawler |
Alpharma's Soothing Guidance Alpharma lowers its financial guidance for 2008. Investors, take note. |
The Motley Fool
February 8, 2008
Brian Lawler |
Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses. |
The Motley Fool
August 25, 2008
Brian Lawler |
King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market. |
The Motley Fool
February 28, 2008
Brian Lawler |
Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful. |
The Motley Fool
August 22, 2007
Brian Orelli |
Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note. |
The Motley Fool
February 28, 2007
Brian Lawler |
Alpharma's Just All Right Drugmaker Alpharma announces its fourth-quarter financial results and reiterates guidance for 2007. |
The Motley Fool
April 27, 2007
Brian Lawler |
Cephalon's Earnings Surprise The drugmaker raises its earnings guidance for the year. With no serious competition for its lead compounds in the near term, investors should take a look at the well-run pharma. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness. |
The Motley Fool
September 12, 2008
Brian Lawler |
King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders. |
The Motley Fool
September 29, 2006
Brian Lawler |
Alpharma's Painless Results A new addition to an already successful drug promises good results for investors. |
The Motley Fool
July 2, 2008
Brian Lawler |
DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development. |
The Motley Fool
March 3, 2009
Robert Steyer |
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company. |
The Motley Fool
December 7, 2007
Brian Lawler |
Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy. |
The Motley Fool
June 11, 2008
Brian Lawler |
Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals? |
The Motley Fool
August 14, 2009
Brian Orelli |
The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics. |
The Motley Fool
August 14, 2008
Brian Lawler |
A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA. |
The Motley Fool
October 12, 2010
Travis Hoium |
King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc. |
The Motley Fool
January 25, 2008
Brian Orelli |
Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that. |
The Motley Fool
May 5, 2008
Brian Lawler |
Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week. |
BusinessWeek
August 9, 2004
Gene G. Marcial |
MGI Pharma Has Just What Patients Need Its first major drug, an injection to prevent chemotherapy-induced nausea and vomiting, is on fire in a $1.5 billion market. And turning MGI into a moneymaker. |
The Motley Fool
January 15, 2008
Brian Orelli |
Fewer Generics in Fido's Future TEVA considers selling its small animal-health business. |
The Motley Fool
October 5, 2007
Brian Lawler |
OxyContin in the Crosshairs Again The state of Kentucky sues Purdue Frederick over the monetary burden that abusers of the drug OxyContin place on counties within the state. |
